Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (not Serina Therapeutics, Inc.) on May 13, 2022. The filing serves to announce the company's financial results for the three-month period ended March 31, 2022. AgeX is an emerging growth company incorporated in Delaware, with its principal executive offices in Alameda, California. Its common stock trades on the NYSE American under the symbol AGE.
Key Financial Metrics
The filing text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It explicitly states that the detailed financial results are contained in a press release furnished as Exhibit 99.1 to this report. Consequently, no specific financial metrics can be extracted from the provided text.
Material Changes
The filing does not provide specific data regarding material changes versus the prior comparable period. It only references the issuance of a press release containing the results for the quarter ended March 31, 2022.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing includes a standard disclaimer that statements containing words such as "may," "will," "believes," or "expects" are forward-looking and subject to risks and uncertainties.
- Risk Factors: The company directs investors to its periodic reports filed with the SEC under the heading "Risk Factors" for additional details on factors that could cause actual results to differ materially from anticipated results.
- Management Commentary: No specific management commentary or outlook is provided within the body of this 8-K text; such details are located in the referenced press release (Exhibit 99.1).
Important Facts for Investor Verification
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release dated May 13, 2022), as they are not included in the 8-K text.
- Confirm the company name is AgeX Therapeutics, Inc., as the input metadata incorrectly identified it as Serina Therapeutics, Inc.
- Note that the information in Item 2.02 and the press release is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
- Review the company's most recent periodic reports for the full list of risk factors applicable to the business.